# Assessing the Pharmacokinetics of NKTR-118 in Subjects With Renal Impairment Compared to That in Subjects With Normal Renal Function

> **NCT01372826** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 32 (actual)

## Conditions studied

- Renal Impairment

## Interventions

- **DRUG:** NKTR118 Group1
- **DRUG:** NKTR118 Group 2
- **DRUG:** NKTR118 Group3
- **DRUG:** NKTR118

## Key facts

- **NCT ID:** NCT01372826
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2011-10
- **Final completion:** 2011-11
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2014-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01372826

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01372826, "Assessing the Pharmacokinetics of NKTR-118 in Subjects With Renal Impairment Compared to That in Subjects With Normal Renal Function". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01372826. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*